Key result
Targeting the Fas/Fas-L pathway with nonagonistic antibodies or downstream inactivation represents a potential therapeutic strategy for myocarditis.
Why the study?
Does targeting the Fas/Fas-L pathway improve outcomes in inflammatory heart disease such as myocarditis?
Does targeting the Fas/Fas-L pathway improve outcomes in inflammatory heart disease such as myocarditis?
Targeting the Fas/Fas-L pathway represents a promising but complex molecular therapeutic strategy for inflammatory heart diseases like myocarditis.
No takes yet. Share an insight, caveat, or question.
Should not yet change myocarditis practice; leaves open Fas/Fas-L targeting for prospective trials.
Henriques‐Pons et al. (2009) conducted a review in Inflammatory heart disease (myocarditis). Fas/Fas-L pathway targeted therapies (nonagonistic antibodies or downstream inactivation) was evaluated. Targeting the Fas/Fas-L pathway with nonagonistic antibodies or downstream inactivation represents a potential therapeutic strategy for myocarditis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: